Regulatory Update and Offer Period Extension for Bavarian Nordic
In a recent development concerning Bavarian Nordic, the Offeror, a consortium of Nordic Capital and Permira, announced an extension of their voluntary recommended takeover offer. This decision comes as the Offeror seeks additional time to secure remaining regulatory approvals essential for finalizing the acquisition.
Details of the Offer Extension
The Offeror published a supplement to the Offer Document on a significant date, extending the offer period to 14 October 2025. The extension allows the consortium to fulfill the last outstanding regulatory conditions required for the successful completion of the acquisition of Bavarian Nordic A/S. The governing authorities have already approved the applicable merger controls across several territories, including Australia, China, Saudi Arabia, Switzerland, and the United States.
Regulatory Approvals Achieved
According to the Offeror, various regulatory approvals have been secured regarding merger control, as well as foreign direct investment laws in Germany, Italy, and Denmark. The only regulatory hurdle left is the merger control approval expected from the European Union, anticipated to be cleared by mid-October 2025. The consortium aims to complete the acquisition by the middle of the fourth quarter of 2025, pending these approvals.
Implications for Shareholders
The newly published Supplement includes supplementary information regarding the acceptance condition, which remains unfulfilled as per the most recent communication. Nevertheless, the Board of Directors of Bavarian Nordic continues to recommend the offer to its shareholders, maintaining confidence in the strategic vision underpinning this acquisition.
How the Offer Works
This takeover offer allows shareholders of Bavarian Nordic to sell their stock in exchange for cash. As of now, the offer is valid since late August until the new expiry date in October. The shareholders are encouraged to evaluate the comprehensive offer documents before making their decisions regarding acceptance of the offer.
Looking Ahead: Updated Timetable for the Offer
The updated timeline for the takeover process provides clarity for both existing and potential shareholders. Key dates include the announcement of preliminary results shortly after the extended offer period ends and projected timetable adjustments as various conditions are met.
Important Timetable Dates
- Publication of Supplement: 29 September 2025
- Expiry of the initial offer period: Now obsolete due to extension.
- Expiry of the extended offer period: 14 October 2025 at 11:59 p.m. (CEST)
- Preliminary results announcement: Expected on 15 October 2025
- Settlement dates as set in initial documents remain unchanged, with funds to be transferred to shareholders who accept the offer shortly thereafter.
About Bavarian Nordic
Bavarian Nordic is recognized as a leading global vaccine company dedicated to improving public health through innovative vaccine solutions. Their offerings include highly regarded vaccines for mpox and smallpox, aimed at enhancing global health preparedness. As they continue to develop a strong portfolio of travel vaccines, they remain a preferred partner for governments worldwide.
Frequently Asked Questions
What is the deadline for shareholders to accept the offer?
The deadline for shareholders to accept the offer is now extended to 14 October 2025 at 11:59 p.m. (CEST).
Why was the offer period extended?
The consortium required additional time to secure the outstanding regulatory approvals necessary to proceed with the acquisition.
What approvals have already been obtained?
Regulatory approvals have been obtained from multiple countries, including the United States and several key European countries, with the EU approval pending.
What is the impact of this offer on Bavarian Nordic's shareholders?
Shareholders are being encouraged to read the offer documents thoroughly to understand their options and the benefits of the proposed acquisition.
Who can shareholders contact for more information?
Shareholders can reach out to company representatives listed in the announcement for further inquiries about the offer and its implications.
